Maillard reaction inhibitor
US5621003A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 15, 1995 |
| Grant date | Apr 15, 1997 |
| Priority date | — |
| Expiry date | Aug 15, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A maillard reaction inhibitor comprising, as the principal component, an eight-structural polymer of 3-oxygermylpropionic acid represented by the following stereostructure (I): ##STR1## wherein R represents --CH.sub.2 CH.sub.2 COOH, and m is a weight average polymerization degree calculated on the basis of the weight average molecular weight of propagermanium propyl ester and is 137.+-.84 (137 on average with a standard deviation of .+-.3.sigma.); and having the following minimum constitutional unit: EQU (O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH and the following empirical formula: EQU C.sub.6 H.sub.10 Ge.sub.2 O.sub.7, a method for inhibiting the Maillard reaction, and a method for preventing and treating diseases caused by Maillard reaction such as diabetes and concurrent diseases thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.